指南与共识抗菌药物管理药物不良反应与药物警戒

COVID-19大流行期间开源机构指南推荐意见分析

Open-source institutional guideline recommendations during the COVID-19 pandemic.
指南 / 共识 · Am J Health Syst Pharm · 2020-01-01

该分析检索2020年4月美国105家机构的在线开源COVID-19治疗指南,发现14家(13.3%)有可用指南。

要点

  • 仅13.3%的机构提供在线开源COVID-19治疗指南
  • 支持治疗和临床试验入组是所有指南的主要推荐

核心结论

  • 分析显示各机构对COVID-19的治疗或辅助药物治疗推荐存在差异。

研究设计与样本

  • 于2020年4月12日至14日及4月22日两次检索美国开源在线机构COVID-19治疗指南,初始筛选105家机构,14家(13.3%)有可用指南。

主要发现

  • 所有评估指南的主要推荐为支持治疗和临床试验入组。
  • 2家机构的指南提及羟氯喹与阿奇霉素联合使用。
  • 13家列出羟氯喹剂量推荐的机构中,62%推荐维持剂量为200 mg每日两次。
  • 89%的机构在使用白介素-6抑制剂管理COVID-19时要求感染病学或其他专科会诊。

关键数值与推荐

  • 在13家列出羟氯喹剂量推荐的机构中,62%推荐维持剂量200 mg每日两次。
  • 89%的机构在使用白介素-6抑制剂时要求感染病学或其他专科会诊。
  • 2家机构的指南提及羟氯喹与阿奇霉素联合使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The global coronavirus disease 2019 (COVID-19) pandemic and the search for ways in which to provide the best available care have created unprecedented times in terms of rapidly evolving reports of available treatment options. The primary objective of our analysis was to categorize online, open-source guidance to determine how US institutions approached their recommendations for management of patients with COVID-19 in the early weeks of the pandemic. METHODS: A search for open-source, online institutional guidelines for the treatment of COVID-19 was conducted using predefined criteria. The search was limited to the United States and conducted from April 12 through 14, 2020, and again on April 22, 2020. Searches were conducted at 2 points in time in order to identify changes in treatment recommendations due to evolving literature or institutional experience. Treatment recommendations, including guidance on antiviral therapy, corticosteroid and interleukin-6 inhibitor use, and nutritional supplementation were compared. RESULTS: Of the 105 institutions that met initial screening criteria, 14 institutions (13.3%) had online COVID-19 guidance available. Supportive care and clinical trial enrollment were the primary recommendations in all evaluated guidance. Recommendations to consider antimicrobial and adjunctive therapy varied. Eighty-six percent of guidelines contained recommendations for use, or consideration of use, of hydroxychloroquine. Guidance from 2 institutions mentioned use of hydroxychloroquine and azithromycin in combination. Of the 13 institutions listing hydroxychloroquine dosing recommendations, 62% recommended maintenance dosing of 200 mg twice daily. Infectious diseases or other specialty consultation was required by 89% of institutions using interleukin-6 inhibitors for COVID-19 management. CONCLUSION: Overall, the analysis revealed variability in treatment or supplemental pharmacologic therapy for the management of COVID-19.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Collins CD, Huang J, Potoski BA, et al. Open-source institutional guideline recommendations during the COVID-19 pandemic. Am J Health Syst Pharm. 2020. PMID: 34279573. doi:10.1093/ajhp/zxaa252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。